nach oben

Graefe's Archive for Clinical and Experimental Ophthalmology

Erschienen in:

16.09.2020 | Glaucoma

Atopic dermatitis as a risk factor for severe visual field loss in youth—a retrospective cohort study of glaucoma under steroid treatment

verfasst von: Kenji Suda, Tadamichi Akagi, Hanako Ohashi Ikeda, Takanori Kameda, Tomoko Hasegawa, Masahiro Miyake, Ai Kido, Eri Nakano, Akitaka Tsujikawa

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the characteristics of glaucoma patients who received systemic or topical steroid treatment.

Methods

Patients who received steroid treatment were selected from a total of 4256 patients at our tertiary referral center of glaucoma management between August 2011 and October 2017. Clinical characteristics of the subjects were extracted from clinical records. To evaluate the factors influencing highest intraocular pressure during observation (max-IOP) or mean deviations (MDs) of visual field at the first and last visits, univariate and multivariate regression analyses were performed using a generalized estimating equation.

Results

Three hundred and eighty-two eyes of 196 patients were included in this study. The most frequent disease as the reason for steroid treatment was atopic dermatitis (58 eyes) followed by autoimmune diseases. The patients with atopic dermatitis were significantly younger (38.0 ± 11.2 years old, p < 0.001) and had lower MD (− 9.3 ± 9.1 dB at first visit, p = 0.01; − 10.6 ± 9.2 dB at last visit, p = 0.004) than those with other diseases. In multivariate regression analysis, age and MD at first visit, max-IOP, and atopic dermatitis were correlated with MD at last visit.

Conclusions

The results of the present study suggest that patients with atopic dermatitis carry the risk of irreversible visual field loss even in youth. For earlier detection of high intraocular pressure, reinforcement of ophthalmological screening in management of atopic dermatitis should be recommended.

Nur mit Berechtigung zugänglich

Armaly MF (1965) Statistical attributes of the steroid hypertensive response in the clinically normal eye. I. The demonstration of three levels of response. Investig Ophthalmol 4:187–197

Becker B (1965) Intraocular pressure response to topical corticosteroids. Investig Ophthalmol 4:198–205

Phulke S, Kaushik S, Kaur S, Pandav SS (2017) Steroid-induced glaucoma: an avoidable irreversible blindness. J Curr Glaucoma Pract 11:67–72. https://doi.org/10.5005/jp-journals-10028-1226CrossRefPubMedPubMedCentral

Dibas A, Yorio T (2016) Glucocorticoid therapy and ocular hypertension. Eur J Pharmacol 787:57–71. https://doi.org/10.1016/j.ejphar.2016.06.018CrossRefPubMedPubMedCentral

Fini ME, Schwartz SG, Gao X et al (2017) Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine. Prog Retin Eye Res 56:58–83. https://doi.org/10.1016/j.preteyeres.2016.09.003CrossRefPubMed

Liu D, Ahmet A, Ward L et al (2013) A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy, Asthma Clin Immunol 9:1. https://doi.org/10.1186/1710-1492-9-30CrossRef

Lee YB, Lee JH, Kang MJ et al (2018) Association between allergic diseases and ophthalmologic diseases, including cataracts and glaucoma, using the Korean National Health and Nutrition Examination Survey 2010–2012: A STROBE-compliant article. J Dermatol 45:463–467. https://doi.org/10.1111/1346-8138.14193CrossRefPubMed

Sullivan PW, Ghushchyan VH, Globe G, Schatz M (2018) Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol 141:110–116.e7. https://doi.org/10.1016/j.jaci.2017.04.009CrossRefPubMed

Garbe E, LeLorier J, Boivin JF, Suissa S (1997) Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. J Am Med Assoc 277:722–727. https://doi.org/10.1001/jama.1997.03540330044033CrossRef

10.

Kersey JP, Broadway DC (2006) Corticosteroid-induced glaucoma: a review of the literature. Eye 20:407–416. https://doi.org/10.1038/sj.eye.6701895CrossRefPubMed

11.

Kalina RE (1969) Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 81:788–790. https://doi.org/10.1001/archopht.1969.00990010790006CrossRefPubMed

12.

Dejaco C, Singh YP, Perel P et al (2015) 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 74:1799–1807. https://doi.org/10.1136/annrheumdis-2015-207492CrossRefPubMed

13.

Currò N, Covelli D, Vannucchi G et al (2014) Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy. Thyroid 24:897–905. https://doi.org/10.1089/thy.2013.0445CrossRefPubMed

14.

Lv J, Zhang H, Wong MG et al (2017) Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA - J Am Med Assoc 318:432–442. https://doi.org/10.1001/jama.2017.9362CrossRef

15.

Homma S, Bando M, Azuma A et al (2018) Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig 56:268–291. https://doi.org/10.1016/j.resinv.2018.03.003CrossRefPubMed

16.

Smolen JS, Landewé R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. https://doi.org/10.1136/annrheumdis-2013-204573CrossRefPubMed

17.

Iwase A, Suzuki Y, Araie M et al (2004) The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology 111:1641–1648. https://doi.org/10.1016/j.ophtha.2004.03.029CrossRef

18.

Gordon MO, Torri V, Miglior S, et al (2007) Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 114 https://doi.org/10.1016/j.ophtha.2006.08.031

19.

Jay JL, Murdoch JR (1993) The rate of visual field loss in untreated primary open angle glaucoma. Br J Ophthalmol 77:176–178. https://doi.org/10.1136/bjo.77.3.176CrossRefPubMedPubMedCentral

20.

Takakuwa K, Hamanaka T, Mori K et al (2015) Atopic glaucoma: clinical and pathophysiological analysis. J Glaucoma 24:662–668. https://doi.org/10.1097/IJG.0000000000000069CrossRefPubMed

21.

Emin O, Fatih M, Mustafa O et al (2011) Evaluation impact of long-term usage of inhaled fluticasone propionate on ocular functions in children with asthma. Steroids 76:548–552. https://doi.org/10.1016/j.steroids.2011.02.003CrossRefPubMed

22.

Rauen T, Eitner F, Fitzner C et al (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373:2225–2236. https://doi.org/10.1056/NEJMoa1415463CrossRefPubMed

23.

Jha V, Ganguli A, Saha TK et al (2007) A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 18:1899–1904. https://doi.org/10.1681/ASN.2007020166CrossRefPubMed

24.

MacHardy N, Miles PV, Massengill SF et al (2009) Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol 24:2193–2201. https://doi.org/10.1007/s00467-009-1282-yCrossRefPubMed

25.

Ohtsuka K (1997) Intraocular pressure and proptosis in 95 patients with Graves ophthalmopathy. Am J Ophthalmol 124:570–572. https://doi.org/10.1016/S0002-9394(14)70883-9CrossRefPubMed

26.

Da Silva FLM, De Lourdes Veronese Rodrigues M, Akaishi PMS, Cruz AAV (2009) m Graves’ orbitopathy: frequency of ocular hypertension and glaucoma. Eye 23:957–959. https://doi.org/10.1038/eye.2008.155CrossRefPubMed

27.

Skalicky SE, Borovik AM, Masselos K et al (2008) Prevalence of open-angle glaucoma, glaucoma suspect, and ocular hypertension in thyroid-related immune orbitopathy. J Glaucoma 17:249. https://doi.org/10.1097/IJG.0b013e31816c4db3CrossRefPubMed

28.

Duru N, Van Der Goes MC, Jacobs JWG et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905–1913. https://doi.org/10.1136/annrheumdis-2013-203249CrossRefPubMed

29.

Carli L, Tani C, Querci F et al (2013) Analysis of the prevalence of cataracts and glaucoma in systemic lupus erythematosus and evaluation of the rheumatologists’ practice for the monitoring of glucocorticoid eye toxicity. Clin Rheumatol 32:1071–1073. https://doi.org/10.1007/s10067-013-2214-6CrossRefPubMed

30.

LePoidevin LM, Lee DE, Shi VY (2019) A comparison of international management guidelines for atopic dermatitis. Pediatr Dermatol 36:36–65. https://doi.org/10.1111/pde.13678CrossRefPubMed

31.

Haeck IM, Rouwen TJ, Timmer-De Mik L et al (2011) Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts. J Am Acad Dermatol 64:275–281. https://doi.org/10.1016/j.jaad.2010.01.035CrossRefPubMed

32.

Tamagawa-Mineoka R, Yasuoka N, Ueta M, Katoh N (2018) Influence of topical steroids on intraocular pressure in patients with atopic dermatitis. Allergol Int 10–13. https://doi.org/10.1016/j.alit.2018.01.004

Titel: Atopic dermatitis as a risk factor for severe visual field loss in youth—a retrospective cohort study of glaucoma under steroid treatment
verfasst von: Kenji Suda
Tadamichi Akagi
Hanako Ohashi Ikeda
Takanori Kameda
Tomoko Hasegawa
Masahiro Miyake
Ai Kido
Eri Nakano
Akitaka Tsujikawa
Publikationsdatum: 16.09.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 1/2021
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-020-04925-z

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Atopic dermatitis as a risk factor for severe visual field loss in youth—a retrospective cohort study of glaucoma under steroid treatment

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Association of lateral rectus muscle volume and ocular motility with the abducens nerve in Duane’s retraction syndrome

Predictive factors of enucleation after open globe injuries

Topographic analysis of retinal and choroidal microvasculature according to diabetic retinopathy severity using optical coherence tomography angiography

Ocular fixation and macular integrity by microperimetry in multiple sclerosis

Evaluation of 20-MHz high-frequency ultrasonography for the diagnosis of choroidal nevi

Transepithelial corneal cross-linking assisted by two continuous cycles of iontophoresis for progressive keratoconus in adults: retrospective 5-year analysis

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde